rss
J Neurol Neurosurg Psychiatry 2009;80:498-505 doi:10.1136/jnnp.2008.161018
  • Research paper

Decreased T cell reactivity to Epstein–Barr virus infected lymphoblastoid cell lines in multiple sclerosis

This article has been UnlockedFree via Creative Commons: OPEN ACCESS
  1. M P Pender1,2,
  2. P A Csurhes3,
  3. A Lenarczyk1,
  4. C M M Pfluger3,
  5. S R Burrows4
  1. 1
    The University of Queensland, School of Medicine, Queensland, Australia
  2. 2
    Department of Neurology, Royal Brisbane and Women’s Hospital, Queensland, Australia
  3. 3
    The University of Queensland Centre for Clinical Research, Queensland, Australia
  4. 4
    Queensland Institute of Medical Research, Queensland, Australia
  1. Professor M P Pender, Discipline of Medicine, Clinical Sciences Building, Royal Brisbane and Women’s Hospital, Queensland 4029, Australia; m.hawes{at}uq.edu.au
  • Received 18 August 2008
  • Revised 13 October 2008
  • Accepted 24 October 2008
  • Published Online First 17 November 2008

Abstract

Objective: To investigate T cell and antibody immunity to Epstein–Barr virus (EBV) in multiple sclerosis (MS).

Methods: Immunoglobulin G (IgG) immunity to EBV nuclear antigen 1 (EBNA1) and viral capsid antigen was measured by enzyme linked immunosorbent assays, and T cell immunity was assessed using enzyme linked immunospot assays to measure the frequency of peripheral blood mononuclear cells (PBMC) producing interferon γ in response to autologous EBV infected B cell lymphoblastoid cell lines (LCL) in 34 EBV seropositive healthy subjects and 34 EBV seropositive patients with MS who had not received immunomodulatory therapy in the previous 3 months.

Results: Patients with MS had increased levels of anti-EBNA1 IgG but a decreased frequency of LCL specific T cells compared with healthy subjects. Using purified populations of CD4+ T cells and CD8+ T cells, we showed that the LCL specific response resides predominantly in the CD8+ population, with a frequency 5–7-fold higher than in the CD4+ population. The decreased CD8+ T cell response to LCL in MS was not caused by decreased HLA class I expression by LCL, and LCL from MS patients could be killed normally by HLA matched EBV specific cytotoxic CD8+ T cell clones from healthy subjects. Furthermore, the decreased CD8+ T cell immunity to EBV was not due to a primary defect in the function of CD8+ T cells because EBV specific cytotoxic CD8+ T cell lines could be generated normally from the PBMC of patients with MS.

Conclusion: This quantitative deficiency in CD8+ T cell immunity to EBV might be responsible for the accumulation of EBV infected B cells in the brains of patients with MS.

Footnotes

  • See Editorial Commentary, p 469

  • Funding: This work was supported by project grants from Multiple Sclerosis Research Australia and by an unrestricted research grant from Biogen Idec Australia Pty Ltd.

  • Competing interests: None.

  • Ethics approval: This study was approved by the Royal Brisbane and Women’s Hospital Human Research Ethics Committee and the University of Queensland Medical Research Ethics Committee.

This article has been Unlocked
Free via Creative Commons: OPEN ACCESS

Latest from Practical Neurology

Latest from Practical Neurology

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JNNP.
View free sample issue >>

Free archive
The full back archive is now available for JNNP. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

  • BMJ Careers - Latest Neurology and Neurosurgery jobs

    Latest neurology and neurosurgery jobs